Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 73 - 80 of 12038 results
SEP Licensing Wins Continue—Multinational Litigation Strategy Drives Licensing Win for Ericsson
June 6, 2025| Blog| Viewpoint
President Trump Issues Travel Ban for 19 Countries
June 5, 2025| Alert| Viewpoint
AI Law Moratorium Faces Senate Hurdles, and Federal Judge Limits Chatbots Free Speech — AI: The Washington Report
June 5, 2025| Article| Viewpoint
Should Your Company Use an IP Holding Company? Here’s What You Need to Know
June 5, 2025| Blog| Viewpoint
CMS Sheds Light on its Timeline for Expedited RADV Audits
June 5, 2025| Blog| Viewpoint
New York is Protecting its Consumers, One Budget at a Time
June 3, 2025| Blog| Viewpoint
Sustainable Energy & Infrastructure Client Feature — June 2025
June 2, 2025| Article| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|